Company Filing History:
2 out of 155 
2 out of 4 Years Active: 2014
Title: Innovator Jacques Henri Poupaert: Pioneering Sigma Receptor Ligands
Introduction
Jacques Henri Poupaert, an accomplished inventor based in Brussels, Belgium, has made significant contributions to the field of pharmaceutical sciences. With a remarkable portfolio of two patents, he has focused on developing highly selective sigma receptor ligands that hold promise for various therapeutic applications.
Latest Patents
Poupaert's latest patents revolve around the creation of highly selective sigma receptor ligands. These innovative compounds are characterized by a general formula I that outlines a variety of molecular structures. The ligands are specifically designed to assist in therapies targeting sigma receptors and to alleviate the effects of drug abuse. Key components of the compound include radicals from N-containing heterocycles and diverse moieties such as cyano, nitro, alkyls, and halogens. Similarly, his additional patents, encompassed in general formulas II, III, and IV, emphasize a similar molecular complexity, focusing on a wide array of functional analogs and pharmaceutically acceptable salts that can be utilized in advanced therapeutic contexts.
Career Highlights
Throughout his career, Jacques Henri Poupaert has been affiliated with notable academic institutions including the University of Mississippi and Université Catholique de Louvain. His tenure at these institutions has not only enhanced his research profile but also positioned him as a key player in pharmacological research, particularly in the development of sigma receptor-related compounds.
Collaborations
Collaboration has been a vital aspect of Poupaert's career. He has worked alongside distinguished colleagues such as Christopher R. McCurdy and Christophe Mesangeau. These partnerships have fostered an environment of shared knowledge and innovation, driving forward the advancements in the field of sigma receptor research.
Conclusion
Jacques Henri Poupaert stands out as a prominent inventor in the realm of medicinal chemistry. His innovative patents regarding sigma receptor ligands not only contribute to the scientific community but also offer potential therapeutic benefits for those in need. His work exemplifies the impact that focused research and collaboration can have on advancements in pharmaceuticals, paving the way for future innovations in the field.